GlobeNewswire

Magna Announces Record First Quarter Results

Dela
  • Record quarterly sales, up 21% year over year to $10.79 billion
  • Record quarterly diluted earnings per share of $1.83, increased 21%
  • Cash provided from operating activities of $577 million, up 26%, a first quarter record
  • Paid dividends of $118 million and returned $103 million to shareholders through share repurchases
  • Increased full year outlook for sales and net income attributable to Magna

AURORA, Ontario, May 10, 2018 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) today reported financial results for the first quarter ended March 31, 2018.

Please click HERE for full first quarter Financial Statements and MD&A.

      THREE MONTHS ENDED
      March 31, 2018   March 31, 2017(2)
Reported          
 

Sales
    $   10,792   $   8,900
 

Income from operations before income taxes
    $   851   $   793
 

Net income attributable to Magna International Inc.
    $   660   $   577
 

Diluted earnings per share
    $   1.83   $   1.51


Non-GAAP Financial Measures (1)


Adjusted EBIT
    $   875   $   818
           
Adjusted diluted earnings per share     $   1.84   $   1.53
           
All results are reported in millions of U.S. dollars, except per share figures, which are in U.S. dollars
 
(1)Adjusted EBIT, Adjusted diluted earnings per share and Adjusted EBIT as a percentage of sales are Non-GAAP financial measures that have no standardized meaning under U.S. GAAP, and as a result may not be comparable to the calculation of similar measures by other companies. A reconciliation of these Non-GAAP financial measures is included in the back of this press release.


(2) 2017 amounts included in this Press Release have been adjusted for our adoption of the new revenue standard (Accounting Standard Codification 606) and recast for our new reportable segments.
 

THREE MONTHS ENDED MARCH 31, 2018

We posted sales of $10.79 billion for the first quarter of 2018, an increase of 21% over the first quarter of 2017. The strong growth was achieved despite light vehicle production that declined 2% in North America and was essentially unchanged in Europe, both compared to the first quarter of 2017. We delivered sales growth in each of our operating segments, most notably in our Complete Vehicles segment, which contributed approximately 60% of the increase in sales in the first quarter of 2018.  Excluding the impact of foreign currency translation and net divestitures, sales increased 14%.

Adjusted EBIT increased 7% to $875 million in the first quarter of 2018 resulting in an adjusted EBIT as a percentage of sales of 8.1% in the first quarter of 2018 compared to 9.2% in the first quarter of 2017.  This margin decline was largely driven by an increase in the proportion of sales generated in our Complete Vehicles segment, which have a significantly lower margin as a percentage of sales than our consolidated average, as well as higher launch costs.

Income from operations before income taxes and net income attributable to Magna International Inc. were $851 million and $660 million for the first quarter of 2018, increases of 7% and 14%, respectively, compared to the first quarter of 2017.

Diluted earnings per share increased 21% to $1.83 in the first quarter of 2018, reflecting higher income from operations before income taxes, a lower income tax rate primarily as a result of U.S. tax reform, and the favourable impact of a reduced share count.  Adjusted diluted earnings per share increased 20% to $1.84 compared to $1.53 for the first quarter of 2017.

In the first quarter of 2018, we generated cash from operations before changes in operating assets and liabilities of $1.03 billion, and invested $455 million in operating assets and liabilities. Investment activities for the first quarter of 2018 were $357 million, including $243 million in fixed asset additions and a $114 million increase in investments, other assets and intangible assets.

"We had a strong start to the year, reporting record first quarter results and increasing our outlook for sales and earnings. We continue to position Magna for the emerging mobility ecosystem as demonstrated by the recently announced partnership with Lyft." 
- Don Walker, Magna's Chief Executive Officer

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/9b2aa63a-cfe9-4e35-bfcc-6a0fefca3a3e

RETURN OF CAPITAL TO SHAREHOLDERS

During the three months ended March 31, 2018, we paid dividends of $118 million.  In addition, we repurchased 1.9 million shares for $103 million in the first quarter of 2018.

Yesterday, our Board of Directors declared a quarterly dividend of $0.33 with respect to our outstanding Common Shares for the quarter ended March 31, 2018. This dividend is payable on June 8, 2018 to shareholders of record on May 25, 2018.

SEGMENT SUMMARY(2)

($Millions unless otherwise noted) For the three months ended March 31,
Sales   Adjusted EBIT
      2018       2017       Change         2018     2017     Change  
Body Exteriors & Structures $   4,619   $   4,167   $   452     $   340 $   349 $   (9 )
Power & Vision     3,190       2,963       227         358     328     30  
Seating Systems     1,470       1,335       135         130     116     14  
Complete Vehicles     1,660       527       1,133         19     6     13  
Corporate and Other     (147 )     (92 )     (55 )       28     19     9  
Total Reportable Segments $   10,792   $   8,900   $   1,892     $   875 $   818 $   57  
 

 
  For the three months ended March 31,
    Adjusted EBIT as a
 percentage of sales
            2018     2017   Change  
Body Exteriors & Structures           7.4 %   8.4 %   (1.0 )%
Power & Vision           11.2 %   11.1 %   0.1 %
Seating Systems           8.8 %   8.7 %   0.1 %
Complete Vehicles           1.1 %   1.1 %   0.0 %
Consolidated Average           8.1 %   9.2 %   (1.1 )%
 

For further details on our segment results, please see our Management's Discussion and Analysis of Results of Operations and Financial Position and our Interim Financial Statements.

UPDATED 2018 OUTLOOK

      Current   Previous
Light Vehicle Production (Units)
  North America
  Europe
   

 
 

17.3 million
22.6 million
   

17.4 million
22.4 million
           
Segment Sales
  Body Exteriors & Structures
  Power & Vision
  Seating Systems
  Complete Vehicles
   

 
 

$17.3 - $18.1 billion
$12.3 - $12.9 billion
$5.5 - $5.9 billion
$6.4 - $6.8 billion
   

$16.6 - $17.4 billion
$11.8 - $12.4 billion
$5.3 - $5.7 billion
$6.0 - $6.4 billion
           
Total Sales     $40.9 - $43.1 billion   $39.3 - $41.5 billion
           
Adjusted EBIT Margin(3)     7.9% - 8.2%   7.9% - 8.2%
           
Equity Income (included in EBIT)     $335 - $375 million   $335 - $375 million
           
Interest Expense, net     Approximately $90 million   Approximately $90 million
           
Income Tax Rate(4)     22% - 23%   22% - 23%
           
Net Income attributable to Magna     $2.4 - $2.6 billion   $2.3 - $2.5 billion
           
Capital Spending     Approximately $1.8 billion   Approximately $1.8 billion
           
(3)  Adjusted EBIT Margin is the ratio of Adjusted EBIT to Total Sales.
(4)  The Income Tax Rate has been calculated using Adjusted EBIT and is based on current tax legislation. 
 
   

In this 2018 outlook, we have assumed:

  • 2018 light vehicle production volumes (as set out above);
  • no material unannounced acquisitions or divestitures; and
  • foreign exchange rates for the most common currencies in which we conduct business relative to our U.S. dollar reporting currency as follows:
    · 1 Canadian dollar equals U.S. dollars     0.780
    · 1 euro equals U.S. dollars                       1.225

NON-GAAP FINANCIAL MEASURES RECONCILIATION

Adjusted EBIT
 
The following table reconciles net income to Adjusted EBIT:
   
  For the three months ended March 31,
    2018       2017  
       
Net Income $   669     $   587  
Add:      
  Interest expense, net     21         19  
  Other expense     3         6  
  Income taxes     182         206  
Adjusted EBIT $   875     $   818  
       
       
Adjusted EBIT as a percentage of sales ("Adjusted EBIT margin")      
       
Adjusted EBIT as a percentage of sales is calculated in the table below:
   
  For the three months ended March 31,
    2018       2017  
       
Sales $   10,792     $   8,900  
Adjusted EBIT $   875     $   818  
Adjusted EBIT as a percentage of sales     8.1%         9.2%  
       
       
Adjusted diluted earnings per share      
       
The following table reconciles net income attributable to Magna International Inc. to Adjusted diluted earnings per share:
   
  For the three months ended March 31,
    2018       2017  
       
Net income attributable to Magna International Inc. $   660     $   577  
Add:      
  Other expense     3         6  
Adjusted net income attributable to Magna International Inc. $   663     $   583  
Diluted weighted average number of Common Shares outstanding during the year (millions):     359.9         383.4  
Adjusted diluted earnings per share $   1.84     $   1.53  
 

Certain of the forward-looking financial measures above are provided on a Non-GAAP basis. We do not provide a reconciliation of such forward-looking measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.  To do so would be potentially misleading and not practical given the difficulty of projecting items that are not reflective of on-going operations in any future period. The magnitude of these items, however, may be significant.

This press release together with our Management's Discussion and Analysis of Results of Operations and Financial Position and our Interim Financial Statements are available in the Investor Relations section of our website at www.magna.com/investors and filed electronically through the System for Electronic Document Analysis and Retrieval (SEDAR) which can be accessed at www.sedar.com as well as on the United States Securities and Exchange Commission's Electronic Data Gathering, Analysis and Retrieval System (EDGAR), which can be accessed at www.sec.gov.

We will hold a conference call for interested analysts and shareholders to discuss our first quarter ended March 31, 2018 results on Thursday, May 10, 2018 at 2:30 p.m. EST. The conference call will be chaired by Don Walker, Chief Executive Officer. The number to use for this call from North America is 1-888-224-3708. International callers should use 1-303-223-4397. Please call in at least 10 minutes prior to the call start time. We will also webcast the conference call at www.magna.com. The slide presentation accompanying the conference call will be available on our website Thursday prior to the call.

TAGS
Quarterly earnings, record quarter, financial results, sales growth

INVESTOR CONTACT
Louis Tonelli, Vice-President, Investor Relations 
louis.tonelli@magna.com  |  905.726.7035

MEDIA CONTACT 
Tracy Fuerst, Director of Corporate Communications & PR
tracy.fuerst@magna.com  |  248.631.5396

OUR BUSINESS (5)
We have more than 172,000 entrepreneurial-minded employees dedicated to delivering mobility solutions. We are a mobility technology company and one of the world's largest automotive suppliers with 340 manufacturing operations and 93 product development, engineering and sales centres in 28 countries. Our competitive capabilities include body exteriors and structures, power and vision technologies, seating systems and complete vehicle solutions. Our common shares trade on the Toronto Stock Exchange (MG) and the New York Stock Exchange (MGA). For further information about Magna, visit www.magna.com.

___________________________
(5) Manufacturing operations, product development, engineering and sales centres and employee figures include certain equity-accounted operations.

FORWARD-LOOKING STATEMENTS
We disclose "forward-looking information" or "forward-looking statements" (collectively, "forward-looking statements") to provide information about management's current expectations and plans. Such forward-looking statements may not be appropriate for other purposes.

Forward-looking statements may include financial and other projections, as well as statements regarding our future plans, objectives or economic performance, or the assumptions underlying any of the foregoing, and other statements that are not recitations of historical fact. We use words such as "may", "would", "could", "should", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "aim", "forecast", "outlook", "project", "estimate", "target" and similar expressions suggesting future outcomes or events to identify 
forward-looking statements.

Forward-looking statements in this press release include, but are not limited to, statements related to:

  • The expected benefits of our partnership with Lyft;
  • Magna's forecasts of light vehicle production in North America and Europe;
  • Expected consolidated sales, based on such light vehicle production, including expected split by segment in our Body Exteriors & Structures; Power & Vision; Seating Systems; and Complete Vehicles segments;
  • Consolidated EBIT margin;
  • Consolidated equity income;
  • Net interest expense;
  • Effective income tax rate;
  • Net income;
  • Fixed asset expenditures; and
  • Future returns of capital to our shareholders, including through dividends or share repurchases.

Our forward-looking statements are based on information currently available to us, and are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances.

While we believe we have a reasonable basis for making such forward-looking statements, they are not a guarantee of future performance or outcomes. Whether actual results and developments conform to our expectations and predictions is subject to a number of risks, assumptions and uncertainties, many of which are beyond our control, and the effects of which can be difficult to predict, including, without limitation:

Risks Related to the Automotive Industry 

  • economic cyclicality;
  • intense competition;
  • potential restrictions on free trade;
Customer and Supplier Related Risks

  • concentration of sales with six customers;
  • shifts in market shares among vehicles or vehicle segments;
  • potential loss of a material purchase order;
Manufacturing / Operational Risks

  • product launch risks;
  • operational underperformance;
  • restructuring costs;
  • impairment charges;
  • labour disruptions;
  • supply disruptions;
IT Security Risk

  • IT/Security breach;
Pricing Risks
  • pricing risks between time of quote and start of production;
  • price concessions;
  • commodity costs;
  • declines in scrap steel prices;
Warranty / Recall Risks

  • costs to repair or replace defective products;
  • warranty costs that exceed our warranty provision;
  • costs related to a significant recall;
Acquisition Risks

  • an increase in our risk profile as a result of completed acquisitions;
  • acquisition integration risk;
Other Business Risks

  • risks related to conducting business through joint ventures;
  • our ability to consistently develop innovative products or processes;
  • changing risk profile;
  • risks of conducting business in foreign markets;
  • fluctuations in relative currency values;
  • tax reassessments and exposures related to changes in tax laws;
  • changes in credit ratings assigned to us;
  • the unpredictability of, and fluctuation in, the trading price of our Common Shares;
Legal, Regulatory and Other Risks
  • antitrust and compliance risk;
  • legal claims and/or regulatory actions against us; and
  • changes in laws.

In evaluating forward-looking statements or forward-looking information, we caution readers not to place undue reliance on any forward-looking statement, and readers should specifically consider the various factors which could cause actual events or results to differ materially from those indicated by such forward-looking statements, including the risks, assumptions and uncertainties above which are discussed in greater detail in this document under the section titled "Industry Trends and Risks" and set out in our Annual Information Form filed with securities commissions in Canada and our annual report on Form 40-F filed with the United States Securities and Exchange Commission, and subsequent filings.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Magna International Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum